Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

This publication has 41 references indexed in Scilit:

• Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany
  PharmacoEconomics, 2005
• The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis
  Annals of the Rheumatic Diseases, 2001
• The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients
  Annals of the Rheumatic Diseases, 2001
• What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
  Best Practice & Research Clinical Rheumatology, 2001
• Bedarf an und Versorgung mit Leistungen aus der Pflegeversicherung bei Patienten mit rheumatoider Arthritis*
  Das Gesundheitswesen, 2000
• Leflunomide
  Drugs, 1999
• The total costs of drug therapy for rheumatoid arthritis
  Arthritis & Rheumatism, 1995
• The Underestimated Long Term Medical and Economic Consequences of Rheumatoid Arthritis
  Drugs, 1995
• Use of short‐term efficacy/toxicity tradeoffs to select second‐line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
  Arthritis & Rheumatism, 1992
• The health assessment questionnaire 1992. Status and review
  Arthritis & Rheumatism, 1992